conditions. With respect to the indicated conditions, attention is directed to the fact that unexpected utility is evident from the Kazda Declaration submitted with an amendment dated April 29, 1980 in parent application S.N. 27,540; a copy of that declaration is enclosed herewith for the convenience of the Examiner.

Further with respect to the matter of the utility, attention is directed to the fact that applicants have provided an extensive disclosure with respect to the matter of the utility. Thus, note the specification page 1, lines 27-34 wherein it is pointed out that the compounds used in the invention shows, at very low doses, cerebral-specific action so that it can be used for cerebral insufficiencies and, in particular, cerebral circulatory disturbances of various origins. Note that the specification goes on to point that the subject matter of the invention is particularly suitable for treating cerebral vascular diseases due to age and sclerosis as well as cerebral hypoxidoses, post-traumatic brain damage, general weaknesses in cerebral performance of vascular and metabolic origin, inbalance and other vestibular illnesses and defective version of vascular origin. specification goes on at page 2, line 16 through page 3 line 30 to further outline the outstanding utility of the subject matter involved and of the data which follows clearly shows such advantageous and unexpected activity. The methods being claimed in this case are clearly identified and supported by the disclosure of this application and patent protection for the methods involved is unquestionably warranted and appropriate. In view of the above and in view of the comments and arguments provided, it is submitted that the method claims (the sole claims retained in the case) are certainly allowable. Prompt passage of this case to issue is most earnestly solicited.

Respectfully submitted,
SPRUNG HORN KRAMER & WOODS

By Joseph G. Rolodny Reg. No. 16,970

600 Third Avenue New York, New York 10016

(212) 661-0520